CNR2 and breast carcinoma: In addition, we show, for the first time, that CNR2 activation inhibits the activation of EGFR/IGF-IR signaling pathways and EGF/IGF-I-induced tumorigenic events in ERα- and ERα+ breast cancer subtypes in vitro and in vivo (Figure 7).